1 week | 4 weeks | 24 weeks | |
---|---|---|---|
Neuropathology considered Pathognomonic for CTE | |||
Perivascular p-Tau accumulation | |||
P1: p-Tau immunoreactive neurons | – | x | x |
P2: p-Tau immunoreactive astrocytes | – | x | x |
Neuropathological features Supportive of CTE | |||
P-Tau related pathologies | |||
S1: Cortical p-Tau (preferentially in superficial layers) | – | x | x |
S2: Hippocampal p-Tau | – | – | – |
S3: p-Tau present in subcortical nuclei | |||
Mamillary bodies | – | x | x |
Amygdala | – | – | – |
Thalamus | – | – | – |
S4: Astroglial p-Tau in subpial and periventricular regions | |||
p-Tau immunoreactive astrocytes in the subpial regions | – | x | x |
p-Tau immunoreactive astrocytes in the periventricular regions | – | – | – |
Non-p-Tau related histological pathologies | |||
S5: TDP-43 immunoreactive neuronal cytoplasmic inclusions | |||
Cortex | – | x | x |
Hippocampus | – | – | x |
Amygdala | – | – | – |
Select nonspecific neuropathological features Associated with CTE* | |||
A1: β-amyloid precursor protein depositions | – | – | – |
A2: α-synuclein depositions | – | – | – |
A3: Hemosiderin laden macrophages | x | x | x |
A4: Reactive microglia | – | x | x |
A5: Astrogliosis | x | x | x |
A6: Neuronal loss | – | x | x |
A7: Axonal loss | – | x | x |
A8: Blood brain barrier disruption | X | x | not done |